{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:08:31Z","timestamp":1789949311903,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-6086-2","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T08:38:07Z","timestamp":1567154287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Sami","family":"Antoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Amine","family":"Bayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Dyevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lanoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Smolenschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"6086_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"6086_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.ejca.2012.12.011","volume":"49","author":"M Ducreux","year":"2013","unstructured":"Ducreux M, Adenis A, Pignon JP, et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13\/0503 study). Eur J Cancer. 2013;49:1236\u201345.","journal-title":"Eur J Cancer"},{"key":"6086_CR3","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","volume":"31","author":"LC Ye","year":"2013","unstructured":"Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931\u20138.","journal-title":"J Clin Oncol"},{"key":"6086_CR4","doi-asserted-by":"publisher","first-page":"15049","DOI":"10.3748\/wjg.v20.i41.15049","volume":"20","author":"C De Divitiis","year":"2014","unstructured":"De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. World J Gastroenterol. 2014;20:15049\u201359.","journal-title":"World J Gastroenterol"},{"key":"6086_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1055-9965.EPI-16-0145","volume":"26","author":"JA Meyerhardt","year":"2017","unstructured":"Meyerhardt JA, Kroenke CH, Prado CM, et al. Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente northern California population. Cancer Epidemiol Biomark Prev. 2017;26:30\u20137.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"6086_CR6","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539\u201347.","journal-title":"J Clin Oncol"},{"key":"6086_CR7","doi-asserted-by":"publisher","first-page":"e172319","DOI":"10.1001\/jamaoncol.2017.2319","volume":"3","author":"EMC Cespedes Feliciano","year":"2017","unstructured":"Cespedes Feliciano EMC, Kroenke CH, et al. Association of systemic inflammation and sarcopenia with survival in non-metastatic colorectal cancer: results from the C SCANS study. JAMA Oncol. 2017;3:e172319.","journal-title":"JAMA Oncol"},{"key":"6086_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00520-014-2418-6","volume":"23","author":"HW Jung","year":"2015","unstructured":"Jung HW, Kim JW, Kim JY, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015;23:687\u201394.","journal-title":"Support Care Cancer"},{"key":"6086_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/bjs.10075","volume":"103","author":"G Malietzis","year":"2016","unstructured":"Malietzis G, Currie AC, Athanasiou T, et al. Influence of body composition profile on outcomes following colorectal cancer surgery. Br J Surg. 2016;103:572\u201380.","journal-title":"Br J Surg"},{"key":"6086_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3945\/ajcn.2008.27273","volume":"89","author":"JR Lieffers","year":"2009","unstructured":"Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr. 2009;89:1173\u20139.","journal-title":"Am J Clin Nutr"},{"key":"6086_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr3129w","volume":"9","author":"T Endo","year":"2017","unstructured":"Endo T, Momoki C, Yamaoka M, et al. Validation of skeletal muscle volume as a nutritional assessment in patients with gastric or colorectal cancer before radical surgery. J Clin Med Res. 2017;9:844\u201359.","journal-title":"J Clin Med Res"},{"key":"6086_CR12","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1245\/s10434-016-5360-7","volume":"23","author":"S Chemama","year":"2016","unstructured":"Chemama S, Bayar MA, Lanoy E, et al. Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2016;23:3891\u20138.","journal-title":"Ann Surg Oncol"},{"key":"6086_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/SPC.0000000000000011","volume":"7","author":"S Antoun","year":"2013","unstructured":"Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care. 2013;7:383\u20139.","journal-title":"Curr Opin Support Palliat Care"},{"key":"6086_CR14","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/j.cllc.2016.09.008","volume":"18","author":"B Sj\u00f8blom","year":"2017","unstructured":"Sj\u00f8blom B, Benth J\u0160, Gr\u00f8nberg BH, et al. Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2017;18:e129\u201336.","journal-title":"Clin Lung Cancer"},{"key":"6086_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2174\/18715206113139990322","volume":"13","author":"CM Prado","year":"2013","unstructured":"Prado CM, Maia YL, Ormsbee M, Sawyer MB, Baracos VE. Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics. Anti Cancer Agents Med Chem. 2013;13:1197\u2013203.","journal-title":"Anti Cancer Agents Med Chem"},{"key":"6086_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01635581.2014.894103","volume":"66","author":"M Barret","year":"2014","unstructured":"Barret M, Antoun S, Dalban C, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66:583\u20139.","journal-title":"Nutr Cancer"},{"key":"6086_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/cam4.621","volume":"5","author":"R Ali","year":"2016","unstructured":"Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016;5:607\u201316.","journal-title":"Cancer Med"},{"key":"6086_CR18","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1002\/cncr.30950","volume":"123","author":"EM Cespedes Feliciano","year":"2017","unstructured":"Cespedes Feliciano EM, Lee VS, et al. Muscle mass at the time of diagnosis of non-metastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS study. Cancer. 2017;123:4868\u201377.","journal-title":"Cancer"},{"key":"6086_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","volume":"34","author":"S Blauwhoff-Buskermolen","year":"2016","unstructured":"Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol. 2016;34:1339\u201344.","journal-title":"J Clin Oncol"},{"key":"6086_CR20","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1245\/s10434-016-5188-1","volume":"23","author":"G Malietzis","year":"2016","unstructured":"Malietzis G, Currie AC, Johns N, et al. Skeletal muscle changes after elective colorectal cancer resection: a longitudinal study. Ann Surg Oncol. 2016;23:2539\u201347.","journal-title":"Ann Surg Oncol"},{"key":"6086_CR21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3945\/ajcn.113.060228","volume":"98","author":"CM Prado","year":"2013","unstructured":"Prado CM, Sawyer MB, Ghosh S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr. 2013;98:1012\u20139.","journal-title":"Am J Clin Nutr"},{"key":"6086_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","volume":"28","author":"S Antoun","year":"2010","unstructured":"Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28:1054\u201360.","journal-title":"J Clin Oncol"},{"key":"6086_CR23","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1007\/s00520-017-3755-z","volume":"25","author":"P Atlan","year":"2017","unstructured":"Atlan P, Bayar MA, Lanoy E, et al. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study. Support Care Cancer. 2017;25:3365\u201373.","journal-title":"Support Care Cancer"},{"key":"6086_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629\u201335.","journal-title":"Lancet Oncol"},{"key":"6086_CR25","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","volume":"9","author":"W Shen","year":"2004","unstructured":"Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (Bethesda, Md : 1985). 2004;9:2333\u20138.","journal-title":"J Appl Physiol (Bethesda, Md : 1985)"},{"key":"6086_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997\u20131006.","journal-title":"Appl Physiol Nutr Metab"},{"key":"6086_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1152\/jappl.2000.89.1.104","volume":"89","author":"BH Goodpaster","year":"2000","unstructured":"Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (Bethesda, Md: 1985). 2000;89:104\u201310.","journal-title":"J Appl Physiol (Bethesda, Md: 1985)"},{"key":"6086_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343\u20136.","journal-title":"Control Clin Trials"},{"key":"6086_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/14737140.2017.1298446","volume":"17","author":"MA Bayar","year":"2017","unstructured":"Bayar MA, Antoun S, Lanoy E. Statistical approaches for evaluating body composition markers in clinical cancer research. Expert Rev Anticancer Ther. 2017;17:311\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"key":"6086_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.clnu.2017.05.017","volume":"37","author":"ST McSorley","year":"2018","unstructured":"McSorley ST, Black DH, Horgan PG, McMillan DC. The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer. Clin Nutr. 2018;37:1279\u201385.","journal-title":"Clin Nutr"},{"key":"6086_CR31","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1245\/s10434-018-6395-8","volume":"25","author":"JJ Hopkins","year":"2018","unstructured":"Hopkins JJ, Skubleny D, Bigam DL, Baracos VE, Eurich DT, Sawyer MB. Barriers to the interpretation of body composition in colorectal Cancer: a review of the methodological inconsistency and complexity of the CT-defined body habitus. Ann Surg Oncol. 2018;25:1381\u201394.","journal-title":"Ann Surg Oncol"},{"key":"6086_CR32","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CM Prado","year":"2007","unstructured":"Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264\u20138.","journal-title":"Clin Cancer Res"},{"key":"6086_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13539-011-0030-x","volume":"2","author":"NA Stephens","year":"2011","unstructured":"Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2:111\u20137.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6086_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2012.10.001","volume":"34","author":"MJ Lee","year":"2013","unstructured":"Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Asp Med. 2013;34:1\u201311.","journal-title":"Mol Asp Med"},{"key":"6086_CR35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s12032-011-9894-z","volume":"29","author":"T Poterucha","year":"2012","unstructured":"Poterucha T, Burnette B, Jatoi A. A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med Oncol. 2012;29:1005\u20139.","journal-title":"Med Oncol"},{"key":"6086_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcsm.12337","volume":"9","author":"SA Kurk","year":"2018","unstructured":"Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, Punt CJA, Koopman M, May AM. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2018;9:909\u201319.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6086_CR37","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1152\/japplphysiol.00776.2009","volume":"107","author":"LA Gilliam","year":"2009","unstructured":"Gilliam LA, Ferreira LF, Bruton JD, et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol (1985). 2009;107:1935\u201342.","journal-title":"J Appl Physiol (1985)"},{"key":"6086_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.bjc.6604858","volume":"100","author":"K van Norren","year":"2009","unstructured":"van Norren K, van Helvoort A, Argil\u00e9s JM, et al. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer. 2009;100:311\u20134.","journal-title":"Br J Cancer"},{"key":"6086_CR39","doi-asserted-by":"publisher","first-page":"e109030","DOI":"10.1371\/journal.pone.0109030","volume":"9","author":"P Hojman","year":"2014","unstructured":"Hojman P, Fjelbye J, Zerahn B, et al. Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice. PLoS One. 2014;9:e109030.","journal-title":"PLoS One"},{"key":"6086_CR40","doi-asserted-by":"publisher","first-page":"43442","DOI":"10.18632\/oncotarget.9779","volume":"7","author":"R Barreto","year":"2016","unstructured":"Barreto R, Waning DL, Gao H, Liu Y, Zimmers TA, Bonetto A. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs. Oncotarget. 2016;7:43442\u201360.","journal-title":"Oncotarget"},{"key":"6086_CR41","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s00520-018-4044-1","volume":"26","author":"A van der Werf","year":"2018","unstructured":"van der Werf A, Arthey K, Hiesmayr M, et al. The determinants of reduced dietary intake in hospitalised colorectal cancer patients. Support Care Cancer. 2018;26:2039\u201347.","journal-title":"Support Care Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6086-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T23:07:11Z","timestamp":1598483231000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6086-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6086"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6086-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"15 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients eligible in the current study were enrolled in the ACCORD trial, a prospective multicenter, randomized, open-labelled, non-comparative phase II trial []. The ACCORD study was approved by ethics committee of the Kremlin-Bic\u00eatre hospital and all patients provided informed written consent (clinicaltrials.gov identifier NCT00423696). The additional analyses of clinical data and interpretation of body composition from CT images in the current study were approved by the Gustave Roussy independent ethics committees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"847"}}